QBiotics Offer to open on 13 August 2026
BRISBANE, 12 August 2026
As announced on 5 August 2026, QBiotics Group Limited (QBiotics) is undertaking an offer to raise up to $40,000,000 (Offer) from new and existing shareholders, with a minimum raising of $5,000,000.
QBiotics advises that it has today lodged a replacement prospectus dated 12 August 2026 (Replacement Prospectus) with the Australian corporate regulator, the Australian Securities and Investments Commission (ASIC). The Replacement Prospectus replaces the original prospectus lodged with ASIC on 5 August 2026.
Full details of the Offer are set out in the Replacement Prospectus. The Replacement Prospectus is available to be viewed at https://qbiotics.com/investors/investor-information
From 9:00am (AEST) on 13 August 2026, the Offer will open and the Replacement Prospectus together with the application form will be made available at https://events.miraqle.com/QGLU-offer (subject to ASIC not extending the 7-day exposure period).
FURTHER INFORMATION
EBRU DAVIDSON, INTERIM CEO & MANAGING DIRECTOR
communications@qbiotics.com
or
MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774
ABOUT QBIOTICS
QBiotics Group Limited (QBiotics) is an Australian public unlisted biotechnology company, advancing two clinical-stage, differentiated, small molecule programmes derived from our epoxytigliane platform.
QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, is demonstrating strong efficacy and safety in human clinical Phase II studies. Tigilanol tiglate data has been reported via a Phase II clinical trial in soft tissue sarcoma and a Phase II clinical trial in head and neck cancer. These studies demonstrated objective response rates of 82% and 78%, respectively, in injected tumours with most adverse events consistent with the expected local mode of action of the drug and translational research validating immunological responses. Impressive efficacy and safety outcomes have been achieved in a range of other tumour types under Compassionate Use. No Maximum Tolerated Dose (MTD) was declared in a Phase I safety study and efficacy was reported in nine different tumour types. QBiotics is in planning to implement a Phase II trial in breast cancer in partnership with Unicancer, the French Federation of cancer centres and is currently exploring the treatment of visceral tumours by tigilanol tiglate in a preclinical study.
QBiotics’ second programme is a topically applied regenerative wound therapy EBC-1013 that accelerates wound infill and closure, minimises scarring, and provides local antimicrobial activity. This drug candidate has demonstrated impressive safety and efficacy against chronic and acute wounds and burns in veterinary studies. It is currently in a human Phase I clinical study treating Venous Leg Ulcers.
Patent coverage for tigilanol tiglate and EBC-1013 is broad and Chemistry, Manufacturing and Controls (CMC) is mature, with commercial supply of tigilanol tiglate secured.
QBiotics employs a capital-efficient model that integrates its EcoLogic™ discovery technology with phenotypic screening and early validation in veterinary disease models. This approach enables rapid identification of biologically active molecules, early demonstration of efficacy and safety in complex disease settings in the veterinary environment, and meaningful de-risking prior to human clinical development. Product development is led by an experienced team and complemented by internationally recognised Key Opinion Leaders on our Clinical and Scientific Advisory Boards, who bring deep expertise in oncology, wound healing, antimicrobials, small molecule chemistry and translational drug development.
QBiotics’ business strategy is to advance therapeutic programmes with the potential to address multiple high-value indications through to Phase II proof-of-concept in human clinical studies, and then pursue strategic partnering to accelerate late-stage development and commercialisation.
For more, head to: QBiotics.com or LinkedIn